Aytu Biopharma (AYTU) Cash & Equivalents (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Cash & Equivalents data on file, last reported at $26.7 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 47.0% year-over-year to $26.7 million in Q1 2026; TTM through Mar 2026 was $26.7 million, a 47.0% increase from a year earlier, with the FY2025 full-year figure at $31.0 million, up 54.71% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $26.7 million, down from $30.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for AYTU reached as high as $32.6 million in Q3 2025 and fell as low as $18.2 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $23.0 million across 5 years, with a median of $20.1 million in 2024.
• Across the five-year window, Cash & Equivalents plunged 61.2% in 2022 and surged 62.27% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $19.5 million in 2022, then increased by 0.14% to $19.5 million in 2023, then increased by 4.45% to $20.4 million in 2024, then soared by 47.2% to $30.0 million in 2025, then dropped by 11.02% to $26.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $26.7 million in Q1 2026, $30.0 million in Q4 2025, and $32.6 million in Q3 2025.